.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Harvard Business School
Julphar
Novartis
Cantor Fitzgerald
Citi
Fuji
Express Scripts
Merck
Deloitte

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Aerosols containing salmeterol xinafoate and an anticholinergic medicament
Abstract:This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
Inventor(s): Akehurst; Rachel Ann (Ware, GB), Taylor; Anthony James (Ware, GB), Wyatt; David Andrew (Ware, GB)
Assignee: Glaxo Group Limited (Greenford, GB)
Filing Date:Jun 14, 2000
Application Number:09/593,380
Claims:1. A pharmaceutical aerosol formulation which consists essentially of particulate medicament which is salmeterol xinafoate and an anticholinergic medicament in combination and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w of surfactant based on the weight of the medicament.

2. A pharmaceutical aerosol formulation which consists of particulate medicament which is salmeterol xinafoate and an anticholinergic medicament in combination and 1,1,1,2-tetrafluoroethane as propellant.

3. A formulation as claimed in claim 1 wherein the anticholinergic medicament is selected from the list consisting of ipatropium, atropine, oxitropium and salts thereof.

4. A formulation as claimed in claim 2 wherein the anticholinergic medicament is selected from the list consisting of ipatropium, atropine, oxitropium and salts thereof.

5. A formulation as claimed in claim 3 wherein the anticholinergic medicament is ipratropium or a salt thereof.

6. A formulation as claimed in claim 4 wherein the anticholinergic medicament is ipratropium or a salt thereof.

7. A formulation according to claim 1 wherein the medicament is present in an amount of 0.1 to 1% w/w based on the weight of formulation.

8. A formulation according to claim 2 wherein the medicament is present in an amount of 0.1 to 1% w/w based on the weight of formulation.

9. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation according to claim 1.

10. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation according to claim 2.

11. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation according to claim 5.

12. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation according to claim 6.

13. A pharmaceutical aerosol formulation which consists essentially of particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof and an anticholinergic medicament in combination and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w of surfactant.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
QuintilesIMS
Boehringer Ingelheim
Teva
Baxter
Farmers Insurance
Cerilliant
US Department of Justice
Argus Health
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot